article thumbnail

Paving the way for anti-Abeta active immunotherapy

European Pharmaceutical Review

While new positive clinical data with anti-Abeta mAbs signal tremendous advancement and proof‑of-concept for the whole field, it is believed that the observed effects could still be improved and optimised in terms of greater clinical benefits, lower side effects and enhanced treatment convenience.

article thumbnail

Digital Self-Neuromodulation Therapy for PTSD: Interview with Oded Kraft, CEO of GrayMatters Health

Medgadget

These treatments at times come with a long list of side effects, leaving many patients in search of an effective long-term solution. For some patients with PTSD, psychotherapy may not be an effective option, they may find talking about their traumatic experience stress inducing, untherapeutic or ineffective.

article thumbnail

Female sexual interest drug reaches tipping point with Phase III plans

Pharmaceutical Technology

In 2019, the agency authorized the use of Vyleesi, an injectable form of bremelanotide, for the same condition. What’s more, the World Health Organization did not include it in its 11th revision of the International Classification of Diseases (ICD-11) in 2019, she notes. There are no approved treatments in the EU.